2025-524555-31-00Not yet recruitingPhase 1
A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Aug 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 28 Apr 2026
- Start date
- 1 Oct 2026
- Lead sponsor
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Diseases
- Glioblastoma
- EU CT number
- 2025-524555-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose glioblastoma, a type of brain tumour, has come back. It tests an oncolytic adenovirus immunotherapy given more than once.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Recurrent glioblastoma (the tumour has come back)
Main reasons for not taking part
- Healthy volunteers cannot join
Read by machine on 9 Nov 2026.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Not yet recruiting |
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.